Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.70 |
| ▸ | NPC1 | O15118 | 3/20 | 0.70 |
| ▸ | RAB9A | P51151 | 3/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.70 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 6/20 | 0.65 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.65 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.63 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.63 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.59 |
| ▸ | GRK2 | P25098 | 1/20 | 0.57 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.57 |
| ▸ | PTPN22 | Q9Y2R2 | 4/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6389826 | 1.00 | MEN1 (0.70) | MEN1KMT2AL3MBTL1NPC1RAB9A | |
| SCHEMBL5145153 | 0.83 | KMT2A (0.68) | MEN1KMT2AL3MBTL1NPC1RAB9A | |
| SCHEMBL5145149 | 0.83 | KMT2A (0.68) | MEN1KMT2AL3MBTL1NPC1RAB9A | |
| SCHEMBL6390413 | 0.82 | MEN1 (0.84) | MEN1KMT2AL3MBTL1NPC1RAB9A | |
| SCHEMBL6390408 | 0.82 | MEN1 (0.84) | MEN1KMT2AL3MBTL1NPC1RAB9A | |
| SCHEMBL46551 | 0.81 | SLC1A3 (0.73) | MEN1KMT2AL3MBTL1NPC1RAB9A | |
| SCHEMBL5167537 | 0.80 | MEN1 (0.62) | MEN1KMT2AL3MBTL1NPC1RAB9A | |
| SCHEMBL5167542 | 0.80 | MEN1 (0.62) | MEN1KMT2AL3MBTL1NPC1RAB9A | |
| SCHEMBL5147227 | 0.79 | MEN1 (1.00) | MEN1KMT2AL3MBTL1NPC1RAB9A | |
| SCHEMBL5147232 | 0.79 | MEN1 (1.00) | MEN1KMT2AL3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050282840-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2005-12-22 | — | — | US | disclosed |
| US-6897305-B2 | Calcium channel drugs and uses | THERAVANCE, INC. (US) | 2005-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282840-A1 | Methods of modulating neurotrophin-mediated activity | NGF, BDNF, NTRK2 | MEN1 4004/4885KMT2A 4410/4885L3MBTL1 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.